Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2011-07-19
2011-07-19
Ha, Julie (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S001100
Reexamination Certificate
active
07981867
ABSTRACT:
The use of des-aspartate-angiotensin I, its derivatives and/or analogue thereof in medicine is described. In particular, a method for the treatment and/or prophylaxis of viral infections, for inducing hypoglycaemia and/or for reducing hyperglycaemia, and/or for treatment of hypoglycaemia-related conditions is described.
REFERENCES:
patent: 5773415 (1998-06-01), Sim
patent: 5773416 (1998-06-01), Chehab
patent: 6100237 (2000-08-01), Sim
patent: 6589938 (2003-07-01), Sim
patent: 2003/0086920 (2003-05-01), Sim et al.
patent: WO 01/48247 (2001-07-01), None
patent: WO 02/10438 (2002-02-01), None
patent: WO 2004/050918 (2004-06-01), None
patent: WO 2006/003721 (2006-01-01), None
patent: WO 2007/030082 (2007-03-01), None
Definition of derivative and analog from http://cancerweb.ncl.ac.uk/omd/about.html, pp. 1-5. Accessed Jul. 7, 2005.
Diabetes Mellitus from Merck manual, pp. 1-19. Accessed Nov. 11, 2010.
Obesity from Merck manual, pp. 1-8. Accesssed Nov. 11, 2010.
Bulimia Nervosa from Merck manual, pp. 1-2. Accesssed Nov. 11, 2010.
Rudinger J, “Characteristics of the amino acids as components of a peptide hormone sequence,” Peptide Hormones, JA Parsons Edition, University Park Press, Jun. 1976, pp. 1-7.
“Designing Custom Peptides,” from SIGMA Genosys, pp. 1-2. Accessed Dec. 16, 2004.
Schinzel R, Drueckes P, “The phosphate recognition site ofEscherichia colimaltodextrin phosphorylase,” FEBS, Jul. 1991, 286(1,2): 125-128.
Berendsen HJC, “A Glimpse of the Holy Grail?” Science, 1998, 282: 642-643.
Voet D, Voet JG, Biochemistry, Second Edition, John Wiley & Sons, Inc., 1995, pp. 235-241.
Ngo JT, Marks J, Karplus M, “Computational Complexity, Protein Structure Prediction, and the Levinthal Paradox,” The Protein Folding Problem and Tertiary Structure Prediction, K. Merc Jr. and S. Le Grand Edition, 1994, pp. 491-495.
Bradley CM, Barrick D, “Limits of Cooperativity in a Structurally Modular Protein: Response of the Notch Ankyrin Domain to Analogous Alanine Substitutions in Each Repeat,” J. Mol. Biol., 2002, 324: 373-386.
Diamond J. “The double puzzle of diabetes”, 2003, 423: 599-602, Nature.
Dombrowski et al. “A new procedure for the isolation of plasma membranes, T tubules, and internal membranes from skeletal muscle”, 1996, 270:E667-E676, Am J Physiol.
Fendrick et al. “The economic burden of non-influenza-related viral respiratory tract infection in the United States”, 2003, 163:487-494, Arch Intern Med.
Levitt N.S. et al. “The prevalence and identification of risk factors for NIDDM in urban Africans in Cape Town, South Africa”, 1993, 16:601-607, Diabetes Care.
Johasson et al. “Infection-permissive immunization with influenza virus neuraminidase prevents weight loss in infected mice”, 1993, 11:1037-1039, Vaccine.
Sim M.K. et al. “Degradation of angiotensin I in the endothelium and smooth muscle of the rat aorta”, 1994(a), 45:1524-1527, Biochem Pharmacol.
Sim M.K. et al. “Degradation of angiotensin I to [des-Asp1]angiotensin I by a novel aminopeptidase in the rat hypothalamus”, 1994(b), 48:1043-1046, Biochem Pharmacol.
Sim M.K. and Qui X.S. “Angiotensins in plasma of hypertensive rats and human”, 2003, 111:179-182, Regul Peptides.
Sullivan K.M., et al. “Estimates of the US health impact of influenza”, 1993, 83:1712-1716, Am J Public Health.
Dharmani et al., “Effect of des-aspartate-angiotensin I on the actions of angiotensin II in the isolated renal and mesenteric vasculature of hypertensive and STZ-induced diabetic rats,” Regulatory Peptides 129:213-219 (2005).
Kuba et al., “Angiotensin-converting enzyme 2 in lung diseases,” Curr. Opin. Pharmacol. 6:271-276 (2006).
Min et al., “Effects of des-aspartate-angiotensin I on angiotensin II-induced incorporation of phenylalanine and thymidine in cultured rat cardiomyocytes and aortic smooth muscle cells,” Regulatory Peptides 95:93-97 (2000).
Sim and Yuan, “Effects of des-Asp-angiotensin I on the contractile action of angiotensin II and angiotensin III,” Eur. J. Pharmacol 278:175-178 (1995).
Summers, “International Search Report,” 7 pages, from PCT/SG2006/000264, Australian Patent Office, Woden, Australia (mailed Dec. 8, 2006).
Summers, “Written Opinion of the International Searching Authority,” 7 pages, from PCT/SG2006/000264, Australian Patent Office, Woden, Australia (mailed Dec. 8, 2006).
Tochon-Danguy, “International Preliminary Report on Patentability,” 17 pages, from PCT/SG2006/000264, Australian Patent Office, Woden, Australia (mailed Dec. 14, 2007).
Tochon-Danguy, “Written Opinion of the International Preliminary Examining Authority,” 7 pages, from PCT/SG2006/000264, Australian Patent Office, Woden, Australia (mailed Aug. 27, 2007).
Cooley LLP
Ha Julie
National University of Singapore
LandOfFree
Use of des-aspartate-angiotensin I does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of des-aspartate-angiotensin I, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of des-aspartate-angiotensin I will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2712549